

**Prior Authorization Review Panel**

**Prior Authorization Review Panel**

**CHC-MCO Policy Submission**

A separate copy of this form must accompany each policy submitted for review.  
Policies submitted without this form will not be considered for review.

<b>Plan: PA Health &amp; Wellness</b>	<b>Submission Date: 02/01/2021</b>
<b>Policy Number: PA.CP.PHAR.465</b>	<b>Effective Date: 04/2020</b> <b>Revision Date: 01/2021</b>
<b>Policy Name: Teprotumumab (Tepezza)</b>	
<p><b>Type of Submission – <u>Check all that apply:</u></b></p> <p> <input type="checkbox"/> New Policy  <input checked="" type="checkbox"/> Revised Policy*  <input type="checkbox"/> Annual Review - No Revisions  <input type="checkbox"/> Statewide PDL - <i>Select this box when submitting policies for Statewide PDL implementation and when submitting policies for drug classes included on the Statewide PDL.</i> </p>	
<p><b>*All revisions to the policy <u>must</u> be highlighted using track changes throughout the document.</b></p> <p><b>Please provide any changes or clarifying information for the policy below:</b></p> <p><b>1Q 2021 annual review: corrected erroneous criterion for continued therapy to read “Member does not require surgical ophthalmological intervention”; references reviewed and updated.</b></p>	
<b>Name of Authorized Individual (Please type or print):</b>  <b>Auren Weinberg, MD</b>	<b>Signature of Authorized Individual:</b>  

## Clinical Policy: Teprotumumab (Tepezza)

Reference Number: PA.CP.PHAR.465

Effective Date: 04/2020

Last Review Date: 01/2021

[Coding Implications](#)

[Revision Log](#)

### Description

Teprotumumab (Tepezza™) is an insulin-like growth factor 1 receptor (IGF-1R) inhibitor.

### FDA Approved Indication(s)

Tepezza is indicated for the treatment of thyroid eye disease (TED).

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with PA Health & Wellness® that Tepezza is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Thyroid Eye Disease (must meet all):

1. Diagnosis of Graves' disease with associated TED (i.e., Graves' ophthalmopathy, Graves' orbitopathy);
2. Member has active TED with a clinical activity score (CAS) of  $\geq 4$  (see *Appendix D*);
3. Prescribed by or in consultation with an ophthalmologist;
4. Age  $\geq 18$  years;
5. Documentation of recent (within the last 30 days) FT4 and FT3 levels within the laboratory defined reference range, and one of the following (a or b):
  - a. Member is euthyroid per laboratory-defined reference range with baseline disease under control;
  - b. Member has mild hypo- or hyperthyroidism (defined as free thyroxine [FT4] and free triiodothyronine [FT3] levels  $< 50\%$  above or below the normal limits) with documentation of treatment plan to ensure hypo- or hyperthyroidism is promptly corrected and maintained for duration of treatment with Tepezza;
6. Member has not had previous surgical intervention for TED;
7. Member does not require surgical ophthalmological intervention;
8. Failure of a 4-week trial of a systemic corticosteroid (at up to maximally indicated doses), unless clinically significant adverse effects are experienced or all are contraindicated;
9. Member has not received  $\geq 8$  Tepezza infusions (including the initial 10 mg/kg first infusion);
10. Dose does not exceed a single 10 mg/kg dose followed by seven 20 mg/kg infusions given every 3 weeks.

**Approval duration: 6 months (up to 8 total lifetime infusions)**

##### B. Other diagnoses/indications

1. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53

**II. Continued Therapy**

**A. Thyroid Eye Disease** (must meet all):

1. Currently receiving medication via PA Health & Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.LTSS.PHAR.01) applies;
2. Member is responding positively to therapy as evidenced by both of the following (a and b):
  - a. Reduction in proptosis  $\geq 2$  mm;
  - b. Reduction in CAS from baseline of  $\geq 2$  points;
3. Member has not had previous surgical intervention for TED;
4. Member does not require surgical ophthalmological intervention ;
5. Member has not received  $\geq 8$  Tepezza infusions (including the initial 10 mg/kg first infusion);
6. If request is for a dose increase, new dose does not exceed a total of seven 20 mg/kg infusions given every 3 weeks.

**Approval duration: 6 months (up to 8 total lifetime infusions)**

**B. Other diagnoses/indications**

1. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – PA.CP.PMN.53

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

CAS: clinical activity score

FDA: Food and Drug Administration

TED: thyroid eye disease

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
prednisone	30 mg/day PO	30 mg/day
methylprednisolone (SOLU-Medrol®)	500 mg IV once weekly for weeks 1 to 6, then 250 mg IV once weekly for weeks 7-12	500 mg/week

*Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.*

*Appendix C: Contraindications/Boxed Warnings*  
 None reported

*Appendix D: General Information*

- The Graves' orbitopathy CAS elements below are each assigned a score of 1. Graves' orbitopathy is considered active in patients with a CAS of  $\geq 3$  (Ross et al., 2016 American Thyroid Association Guidelines). The Phase 3 clinical trial evaluating teprotumumab enrolled patients with a CAS of  $\geq 4$  (Smith et al. 2017).
  - Painful feeling behind the globe over last four weeks
  - Pain with eye movement during last four weeks
  - Redness of the eyelids
  - Redness of the conjunctiva
  - Swelling of the eyelids
  - Chemosis (edema of the conjunctiva)
  - Swollen caruncle (flesh body at medial angle of eye)
  - Increase in proptosis  $\geq 2$  mm
  - Decreased eye movements  $\geq 5^\circ$  any direction
  - Decreased visual acuity  $\geq 1$  line on Snellen chart

**V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
TED	Initial: 10 mg/kg IV one time dose Maintenance: 20 mg/kg IV every 3 weeks for seven infusions	See dosing regimen

**VI. Product Availability**

Single-dose vial: 500 mg

**VII. References**

1. Tepezza Prescribing Information. Lake Forest, IL: Horizon Therapeutics USA, Inc.; January 2020. Available at: <https://www.hzndocs.com/TEPEZZA-Prescribing-Information.pdf>. Accessed November 4, 2020.
2. NCT03298867 in ClinicalTrials.gov. NIH U.S. National Library of Medicine. Accessed January 15, 2020.
3. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. *Thyroid* 2016; 26:1343.
4. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. *Clin Endocrinol (Oxf)* 1997; 47:9.
5. Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for Thyroid-Associated Ophthalmopathy. *NEJM* 2017; 376 (18): 1748-1761.

<b>Reviews, Revisions, and Approvals</b>	<b>Date</b>	<b>P&amp;T Approval Date</b>
Policy created.	04/2020	
Added requirement that member has not had previous surgical intervention for TED consistent with clinical trial exclusion criteria.	07/2020	
1Q 2021 annual review: corrected erroneous criterion for continued therapy to read “Member does not require surgical ophthalmological intervention”; references reviewed and updated.	01/2021	